NanoViricides Reports That Oral Administration of FluCide® Anti-Influenza Drug Candidates Led to Survival Improvements Comparable to IV Administration and Was Far Superior to Oseltamivir, in a Highly Lethal Animal Model
07:00 EDT 20 Aug 2012 | Businesswire
This article has expired, however you can still
download the PDF.
Preview:
NanoViricides, Inc. (OTCBB: NNVC)
(the "Company") announced today that anti-influenza drug candidates
under its FluCideâ„¢ program, when given orally, were nearly as effective
as when administered as IV injections. Two different...
Other Sources for this Article
NanoViricides, Inc.
Amanda Schuon, 310-550-7200
info@nanoviricides.com
More From BioPortfolio on "NanoViricides Reports That Oral Administration of FluCide® Anti-Influenza Drug Candidates Led to Survival Improvements Comparable to IV Administration and Was Far Superior to Oseltamivir, in a Highly Lethal Animal Model"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
